Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study

被引：0
|
作者：
Marme, F. [1 ]
Hilpert, F. [2 ]
Welslau, M. [3 ]
Grabowski, J. P. [4 ,5 ]
Schneeweiss, A. [6 ,7 ]
Hartkopf, A. D. [8 ]
Becker, S. [9 ]
Runnebaum, I. [10 ]
Bauerschlag, D. [11 ]
Fasching, P. [12 ]
Brandi, C. [13 ]
Rehbein, J-K. [14 ]
Glowik, R. [15 ]
Sehouli, J. [16 ]
机构：
[1] UMM Univ Klinikum Mannheim, Dept Gynecol Oncol, Med Fak, Mannheim, Germany
[2] Krankenhaus Jerusalem, Mammazentrum, Hamburg, Germany
[3] Klinikum Aschaffenburg, Hamato Onkol Schwerpunktpraxis, Aschaffenburg, Germany
[4] Univ Klin Charite, Dept Gynecol, Berlin, Germany
[5] Campus Virchow Klinikum, Berlin, Germany
[6] Univ Hosp, Div Gynecol Oncol, Natl Ctr Tumor Dis NCT, Gynecol Oncol, Heidelberg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Tuebingen, Ctr Womens Hlth Dept, Tubingen, Germany
[9] Goethe Univ Frankfurt Main, Dept Obstet & Gynecol, Campus Westend, Frankfurt, Germany
[10] Friedrich Schiller Univ Jena, Gynecol & Reprod Med, Jena, Germany
[11] Univ Hosp UKSH, Gynecol Oncol, Kiel, Germany
[12] Univ Klinikum Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
[13] Agaples Med Versorgungszentrum Frankfurt gGmbH, Frauenheilkunde Gynakol, Frankfurt, Germany
[14] Stadt Krankenhaus Kiel GmbH, Frauenklin, Kiel, Germany
[15] AstraZeneca GmbH, Med Affairs, Hamburg, Germany
[16] Charite, Gynecol, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
802P
引用
收藏
页码：S535 / S536
页数：2
相关论文
共 50 条
  • [31] Maintenance rucaparib after secondary cytoreductive surgery for platinum-sensitive relapsed ovarian cancer: a real-world multicentre study
    Palo, Upasana
    Mondal, Debapriya
    Ghosh, Anik
    Chakraborti, Basumita
    Roy, Somnath
    Bhaumik, Jaydip
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A242 - A242
  • [32] Maintenance therapy utilization in platinum-sensitive recurrent epithelial ovarian cancer: A 'real-world' analysis
    Moss, H. A.
    Havrilesky, L. J.
    Kauff, N. D.
    Secord, A. A.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 204 - 204
  • [33] REPEATED USE OF MAINTENANCE THERAPY OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSE OF OVARIAN CANCER
    Khokhlova, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A478 - A478
  • [34] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [35] Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain
    Sagrado, Miguel Angel Rodriguez
    Criado, Javier Alvarez
    Pena, Ainhoa Elisa Arenaza
    Escudero-Vilaplana, Vicente
    Olias, Carlos Folguera
    Fernandez, Marta Herrero
    Martinez Nieto, Concepcion
    Salvador, Ana Rosa Rubio
    Fenollera, Patricia Sanmartin
    Castillo, Maria Jose Vazquez
    TARGETED ONCOLOGY, 2025, : 319 - 327
  • [36] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
    Ledermann, Jonathan A.
    Lortholary, Alain
    Penson, Richard T.
    Gibbs, Emma
    Provencher, Diane M.
    Bruchim, Ilan
    Huzarski, Tomas
    Barretina-Ginesta, Maria Pilar
    Sabbatini, Roberto
    Mileshkin, Linda R.
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Matsumoto, Koji
    Sonke, Gabe S.
    Mikheeva, Olga N.
    Kim, Jae-Weon
    Girotto, Gustavo Colagiovanni
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] ECONOMIC IMPACT OF OLAPARIB IN PATIENTS WITH PLATINUM SENSITIVE RELAPSED BRCA MUTATED EPITHELIAL OVARIAN CANCER IN SPAIN
    Delgado-Ortega, L.
    Moya-Alarcon, C.
    Carcedo, D.
    Villacampa, A.
    Cordero, L.
    VALUE IN HEALTH, 2016, 19 (07) : A718 - A718
  • [38] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: US retrospective cohort study.
    Eskander, Ramez Nassef
    Alam, Naufil
    Long, Grainne H.
    Ozgoren, Ozan
    Ambler, Will
    Volpe, Stephanie
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    de Jonge, M.
    Hong, S. H.
    Park, Y. H.
    Wolfer, A.
    Brown, J.
    Ferguson, M.
    Gore, M. E.
    Alvarez, R. H.
    Gresty, C.
    Angell, H.
    Meyer, K.
    Learoyd, M.
    Tang, M.
    Lanasa, M.
    Herbolsheimer, P.
    Domchek, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 247
12345